Internal auditory canal metastasis as the only brain lesion in progressive lung adenocarcinoma: Case report and literature review Authors: Mohamed Yassine Boujnah, Mouna Ben Rejeb, Molka Mezghani, Ghada Abdessatar, Lotfi Kochbati Published: 2026 ABSTRACT BackgroundMetastases to the internal auditory canal (IAC) are exceptionally rare, especially as a solitary lesion without associated parenchymal brain or leptomeningeal involvement. Lung adenocarcinomas with a signet-ring cell component are aggressive and prone to early dissemination.Case presentationWe report a 64-year-old man with stage IV lung adenocarcinoma with a signet-ring cell component who developed rapidly progressive left-sided facial palsy, vertigo, and hearing loss. Brain MRI revealed a solitary enhancing lesion in the left IAC. Considering the clinical context and rapid symptom progression, a metastatic lesion was suspected. The patient was treated with corticosteroids and radiotherapy. At three-week follow-up, he showed marked improvement in vertigo and hearing, with partial recovery of facial nerve function (House–Brackmann grade III).ConclusionThis case highlights the importance of recognizing rare sites of metastasis in patients with known malignancy. Early diagnosis and prompt treatment with a multidisciplinary approach can lead to meaningful neurological improvement and symptom relief, even in the context of ongoing systemic disease. Clinicians should be alert for IAC metastases when acute cochleovestibular or facial nerve symptoms occur. Introduction Brain metastases are a frequent complication of advanced lung adenocarcinoma and represent a major cause of neurological morbidity. Tumors containing a signet-ring cell component are associated with aggressive biological behavior and early systemic dissemination. In contrast, metastatic involvement of the internal auditory canal (IAC) is exceedingly rare. The vast majority of lesions arising in the IAC and cerebellopontine angle (CPA) are benign, most commonly vestibular schwannomas. Because metastatic lesions may closely mimic schwannomas both clinically and radiologically, diagnosis may be challenging, particularly when the IAC lesion is solitary. We report a case of isolated IAC metastasis occurring during systemic progression of signet-ring cell lung adenocarcinoma, without associated parenchymal or leptomeningeal brain involvement, highlighting the importance of clinical context and rapid symptom evolution in guiding diagnosis and management. Case presentation A 64-year-old male active smoker was diagnosed in September 2024 with stage IV (cT4N0M1a) lung adenocarcinoma with a signet-ring cell component, confirmed by mediastinal and pleural biopsies. First-line systemic chemotherapy with cisplatin–vinorelbine (six cycles) was administered but resulted in radiological disease progression. Second-line docetaxel (three cycles) was subsequently given. A body CT scan performed in November 2025 demonstrated further systemic progression, including enlargement of the right mediastino-pulmonary mass and new adrenal, nodal, and ipsilateral pulmonary metastases. No intracranial lesions were identified on the available imaging, however, no dedicated brain imaging had been performed at that time. In December 2025, the patient developed rapidly progressive left-sided peripheral facial palsy, associated with ipsilateral hearing loss, vertigo, and gait instability. On neurological examination, the patient exhibited a left peripheral facial nerve palsy, graded as House–Brackmann IV (Fig. 1), accompanied by ipsilateral hypoacusis and an unstable gait consistent with a static cerebellar syndrome. No other cranial nerve deficits were observed. Nystagmus was absent, and there were no signs of intracranial hypertension.Fig. 1Clinical photograph demonstrating left peripheral facial nerve palsy, graded as House–Brackmann grade IV on neurological examination. Clinical photograph demonstrating left peripheral facial nerve palsy, graded as House–Brackmann grade IV on neurological examination. Brain MRI performed in December 2025 (Fig. 2) demonstrated a contrast-enhancing expansile lesion within the left internal auditory canal, measuring 15 mm in width and 7 mm in anteroposterior dimension, extending to the fundus of the canal after gadolinium injection. The lesion involved the vestibulocochlear and facial nerve bundle, without extension into the cerebellopontine angle (CPA). No supratentorial or infratentorial parenchymal metastases were identified.Fig. 2Gadolinium-enhanced T1-weighted brain MRI. (A) Axial and (B) coronal views demonstrating an enhancing lesion confined to the left internal auditory canal (arrows), without evidence of cerebellopontine angle extension or associated parenchymal brain metastasis. Gadolinium-enhanced T1-weighted brain MRI. (A) Axial and (B) coronal views demonstrating an enhancing lesion confined to the left internal auditory canal (arrows), without evidence of cerebellopontine angle extension or associated parenchymal brain metastasis. Given the rapid onset of symptoms, the known systemic progression, and the strong clinicoradiological concordance, metastatic involvement of the IAC was favored over vestibular schwannoma. Histologic confirmation was not pursued due to the anatomical constraints of the IAC, procedural risks, and the limited impact on management. The patient was initiated on corticosteroid therapy with prednisone 40 mg daily. Given the rapid neurological deterioration, he subsequently received palliative three-dimensional conformal radiotherapy (3D-CRT) targeted to the IAC lesion, stereotactic radiotherapy was not used in this case. A total dose of 20 Gy in 5 fractions was delivered in January 2026. Treatment was well tolerated without acute toxicity. At three-week follow-up, the patient reported marked improvement in vertigo and hearing, along with partial recovery of facial nerve function, which had improved to House–Brackmann grade III. Third-line systemic therapy with gemcitabine is planned for ongoing systemic disease control. Discussion Metastases to the internal auditory canal (IAC) are exceedingly rare, representing only 0.3–0.7% of all lesions in the IAC and cerebellopontine angle (CPA) region [1,2]. In the largest systematic review of 102 IAC metastases, lung cancer was the most common primary tumor, accounting for approximately 21% of cases. Interestingly, bilateral involvement is frequent, occurring in about 53% of cases, often in association with leptomeningeal disease [3]. However, solitary IAC metastasis without associated parenchymal brain involvement, as observed in our patient, remains distinctly uncommon. To highlight this, Table 1 summarizes previously published cases of isolated IAC metastases along with our case.Table 1Published cases of solitary internal auditory canal metastases without parenchymal brain involvement at presentation.Table 1Author, YearAge/SexPrimary TumorHistologyLateralityBiopsyTreatmentOutcomeDe Boos, 2025 [4]59/MLung CancerADKLeft IACYesSRS + CTRadiological response died at 9 monthsUeyama, 2003 [5]56/MProstate cancerADKLeft IACYesSRSRadiological responseChang, 2009 [6]58/MLung CancerADKRight IACNoTranslabyrinthine resection +EBRT (30 Gy)Contralateral IAC and brain metastases at 5 monthsSchrock, 2006 [7]60MLung CancerSCCRight IACNoTranslabyrinthine resection + CTBrain and leptomeningeal progressionOur case, 202664 MLung CancerADKLeft IACNo3D-CRT (20 Gy)Clinical improvementAbbreviations: ADK, adenocarcinoma; SCC, squamous cell carcinoma; IAC, internal auditory canal; SRS, stereotactic radiosurgery; CT, chemotherapy; EBRT, external beam radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy. Table 1Published cases of solitary internal auditory canal metastases without parenchymal brain involvement at presentation.Table 1Author, YearAge/SexPrimary TumorHistologyLateralityBiopsyTreatmentOutcomeDe Boos, 2025 [4]59/MLung CancerADKLeft IACYesSRS + CTRadiological response died at 9 monthsUeyama, 2003 [5]56/MProstate cancerADKLeft IACYesSRSRadiological responseChang, 2009 [6]58/MLung CancerADKRight IACNoTranslabyrinthine resection +EBRT (30 Gy)Contralateral IAC and brain metastases at 5 monthsSchrock, 2006 [7]60MLung CancerSCCRight IACNoTranslabyrinthine resection + CTBrain and leptomeningeal progressionOur case, 202664 MLung CancerADKLeft IACNo3D-CRT (20 Gy)Clinical improvementAbbreviations: ADK, adenocarcinoma; SCC, squamous cell carcinoma; IAC, internal auditory canal; SRS, stereotactic radiosurgery; CT, chemotherapy; EBRT, external beam radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy. Published cases of solitary internal auditory canal metastases without parenchymal brain involvement at presentation. Abbreviations: ADK, adenocarcinoma; SCC, squamous cell carcinoma; IAC, internal auditory canal; SRS, stereotactic radiosurgery; CT, chemotherapy; EBRT, external beam radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy. Metastatic spread to the IAC is believed to occur either via hematogenous dissemination through the internal auditory artery or by leptomeningeal extension. Bilateral involvement is frequently reported and is often associated with leptomeningeal disease, which carries a poorer prognosis. In contrast, our patient presented with unilateral disease and no radiological evidence of meningeal carcinomatosis, highlighting a rare pattern of isolated hematogenous spread. This feature underscores the uniqueness of the case, as solitary, unilateral IAC metastases without concurrent parenchymal or meningeal involvement are exceedingly uncommon [8]. Rapid-onset cochleovestibular symptoms, including hearing loss (often sudden or rapidly progressive), tinnitus, vertigo, and facial nerve dysfunction, represent important clinical red flags for IAC metastases. These manifestations can occasionally be the initial presentation of an occult lung cancer or indicate leptomeningeal disease [9]. In patients with a known malignancy, the abrupt onset and rapid progression of such symptoms should strongly raise suspicion for metastatic involvement. In contrast, vestibular schwannomas typically follow a slow, indolent course. The acute progression of facial palsy, as observed in our patient, was therefore a crucial diagnostic element that distinguished metastatic disease from a benign schwannoma. This rapid neurological deterioration, combined with the patient's oncological history, guided the clinical decision-making toward early intervention rather than delayed histologic confirmation. Magnetic resonance imaging (MRI) with gadolinium remains the imaging modality of choice for evaluating suspected internal auditory canal (IAC) metastases. Lesions typically demonstrate contrast enhancement along the facial (VII) and vestibulocochlear (VIII) nerves and within the IAC, occasionally accompanied by additional CNS or leptomeningeal enhancement [9]. Fluorodeoxyglucose positron emission tomography (FDG PET/CT) may reveal bilateral IAC uptake and can assist in identifying the primary tumor [10]. Radiological differentiation from vestibular schwannoma can be challenging, as both entities enhance with gadolinium and may extend into the cerebellopontine angle. Consequently, the clinical context and symptom kinetics are critical for accurate diagnosis. Although histologic confirmation via biopsy may be considered, such procedures are technically demanding and carry a significant procedural risk. In our patient, the high clinicoradiological probability of metastatic disease, combined with rapid systemic progression, justified proceeding directly to palliative treatment without biopsy. Treatment of IAC metastases is generally individualized and primarily palliative, depending on systemic disease burden and neurological compromise. For solitary or limited IAC metastases, stereotactic radiotherapy can achieve effective local control and partial symptom improvement [11,12]. Systemic therapy can be tailored according to tumor-specific molecular alterations identified by next-generation sequencing (NGS). Targeted agents directed against actionable mutations may reduce the burden of both IAC and other brain metastases, complementing local therapy. In our patient, stereotactic radiotherapy was not used. Given the presence of uncontrolled extracranial disease and the overall palliative context, a three-dimensional conformal radiotherapy (3D-CRT) approach was considered more appropriate. Molecular testing (including ALK, ROS1, and KRAS alterations) was not performed, mainly due to limited access to molecular diagnostics in our setting, consequently, targeted systemic therapy could not be considered. The patient therefore received palliative corticosteroids followed by 3D-CRT targeting the IAC lesion. This approach was well tolerated and led to marked improvement of vertigo and hearing, with partial recovery of facial nerve function (House–Brackmann grade III) at three-week follow-up. Overall prognosis in patients with IAC metastases is largely determined by the extent of systemic disease. Nevertheless, early recognition and prompt local therapy can result in meaningful improvement of neurological function, symptom relief, and quality of life, even in the setting of progressive extracranial disease. This underscores the importance of timely diagnosis and individualized management in rare, solitary IAC metastases. Conclusion Solitary internal auditory canal metastasis from lung adenocarcinoma is exceptionally rare. Rapidly progressive facial palsy, vertigo, and hearing loss in a patient with known malignancy should raise suspicion for metastasis. Early recognition and treatment with corticosteroids and radiotherapy, guided by a multidisciplinary approach, can lead to meaningful neurological improvement. This case emphasizes the importance of considering rare metastatic sites and collaborative management in clinical practice. Patient consent Written informed consent for publication was obtained from the patient. Funding No specific funding was received for this work. CRediT authorship contribution statement Mohamed Yassine Boujnah: Conceptualization, Data curation, Investigation, Resources, Writing – original draft. Mouna Ben Rejeb: Data curation, Investigation, Supervision, Writing – review & editing. Molka Mezghani: Data curation, Resources, Writing – review & editing. Ghada Abdessatar: Data curation, Resources, Writing – review & editing. Lotfi Kochbati: Validation, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.